Kineta, Inc. (NASDAQ:KA) Forecasted to Post Q2 2023 Earnings of ($0.52) Per Share

Posted by on Jun 24th, 2023

Kineta, Inc. (NASDAQ:KA – Get Rating) – Stock analysts at Zacks Small Cap issued their Q2 2023 earnings per share (EPS) estimates for shares of Kineta in a research report issued to clients and investors on Tuesday, June 20th. Zacks Small Cap analyst J. Vandermosten expects that the company will post earnings of ($0.52) per share for the quarter. The consensus estimate for Kineta’s current full-year earnings is ($2.19) per share. Zacks Small Cap also issued estimates for Kineta’s Q3 2023 earnings at ($0.46) EPS, Q4 2023 earnings at ($0.33) EPS, FY2023 earnings at ($1.93) EPS, FY2024 earnings at ($1.41) EPS and FY2025 earnings at ($1.35) EPS.

Separately, HC Wainwright reissued a “buy” rating on shares of Kineta in a research report on Monday, May 1st.

Kineta Trading Up 1.2 %

Shares of NASDAQ:KA opened at $2.63 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.80 and a quick ratio of 0.80. Kineta has a 1 year low of $2.16 and a 1 year high of $15.54. The business’s 50-day moving average price is $3.45.

Kineta (NASDAQ:KA – Get Rating) last issued its earnings results on Thursday, May 11th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.05). Kineta had a negative return on equity of 1,449.31% and a negative net margin of 660.61%. The firm had revenue of $0.28 million for the quarter.

Institutional Investors Weigh In On Kineta

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC bought a new position in Kineta during the 1st quarter worth $34,000. CIBC Asset Management Inc bought a new position in Kineta during the 1st quarter worth $45,000. Renaissance Technologies LLC bought a new position in Kineta during the 4th quarter worth $111,000. Finally, Artal Group S.A. bought a new position in Kineta during the 4th quarter worth $197,000. 3.36% of the stock is owned by institutional investors and hedge funds.

About Kineta

(Get Rating)

Kineta, Inc is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. Its immuno-oncology focused platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance. The company was founded by Shawn P. Iadonato and Charles L.

Read More

Earnings History and Estimates for Kineta (NASDAQ:KA)

Receive News & Ratings for Kineta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kineta and related companies with MarketBeat.com's FREE daily email newsletter.